Lv614
2210 积分 2025-05-24 加入
Time to improvement following teprotumumab treatment of thyroid eye disease: real world experience
2个月前
已完结
Effects of Teprotumumab and Role of Human Leukocyte Antigens Markers in Patients With Thyroid Eye Disease
2个月前
已完结
The Rate of Re-treatment in Patients Treated with Teprotumumab
2个月前
已完结
Glycemic Trends in Patients with Thyroid Eye Disease Treated with Teprotumumab in 3 Clinical Trials
2个月前
已完结
Medical Therapy in Patients with Moderate to Severe, Steroid-Resistant, Thyroid Eye Disease
2个月前
已完结
Alternaria fungal dacryocystitis with cutaneous fistula: a case report
2个月前
已完结
Treat and Extend Anti‐VEGF Treatment Regimens for Neovascular Age‐Related Macular Degeneration: To Stop or Not to Stop?
2个月前
已完结
STRICT PRO RE NATA VERSUS TREAT-AND-EXTEND REGIMENS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
2个月前
已完结
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial
2个月前
已完结
Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration
2个月前
已完结
皖公网安备34019202002308
